Access without continuity is a different thing.
At the intersection of digital convenience and corporate cost-cutting, a quiet restructuring of American obesity care is underway. Telehealth companies are racing to fill the prescribing space for GLP-1 drugs just as the employers who fund most workers' health coverage prepare to abandon them by 2027. Primary care physicians — who carry the full weight of a patient's medical history — are watching this convergence with alarm, not because the technology is malicious, but because the architecture of speed and efficiency may be fundamentally incompatible with the slow, relational work that chronic disease demands.
- Telehealth platforms are aggressively entering the GLP-1 prescribing market, offering fast, remote access to blockbuster obesity drugs with little of the longitudinal oversight that primary care relationships provide.
- Primary care doctors warn that transactional video visits cannot replicate years of patient history — missing contraindications like thyroid cancer or pancreatitis that a longtime physician would catch.
- Major US employers, overwhelmed by the rising cost of GLP-1 medications as demand surges, are quietly planning to eliminate coverage from their health plans by 2027, leaving millions of workers exposed.
- Patients caught in the middle — too wealthy for government assistance, too financially stretched to pay out of pocket — face the sharpest consequences, with few safe harbors in either direction.
- The collision of telehealth expansion and employer retreat is accelerating the formation of a two-tiered system: comprehensive care for those with resources, and largely unregulated transactional prescribing for everyone else.
American medicine is moving in two contradictory directions at once when it comes to obesity treatment. Telehealth companies are aggressively expanding into GLP-1 drug prescribing — offering video visits, prescriptions, and doorstep delivery with a speed and efficiency that traditional medicine cannot match. At the same time, major US employers are preparing to drop coverage for these same medications by 2027, as costs spiral and the number of workers requesting them grows. The doctors most troubled by this collision are primary care physicians — the ones who have managed patients for years, know their full histories, and bear responsibility when something goes wrong.
The concern is structural, not moral. A telehealth prescriber working from a checklist cannot know whether a patient has a history of thyroid cancer, pancreatitis, or a family predisposition to complications. A primary care doctor who has seen that same patient for a decade does. Obesity treatment is not a single transaction — it requires monitoring for side effects over months, integration with other medications, and ongoing adjustment. The telehealth model, built for speed and volume, is not designed for that kind of sustained attention.
The economic pressure compounds the clinical one. As employers cut GLP-1 coverage, patients who have been taking these drugs and seeing results will face a hard choice: pay full price out of pocket, stop the medication, or find another path. Those in the middle — earning too much for government assistance, too little to absorb thousands of dollars a year in drug costs — will have the fewest options.
What is taking shape is a two-tiered system. Patients with resources or comprehensive insurance will have access to a mix of primary care and telehealth providers. Everyone else will be served largely by telehealth companies operating with minimal oversight and no continuity of care. Primary care doctors are not opposed to telehealth or to these medications. Their alarm is about what happens when the organizing principles of care become speed and cost-cutting — and the patient's long-term health becomes secondary to the transaction.
The machinery of American medicine is grinding in two directions at once. On one side, telehealth companies are moving aggressively into the business of prescribing GLP-1 drugs—the blockbuster obesity medications that have become some of the most sought-after pharmaceuticals in the country. On the other side, the employers who foot the bill for millions of workers' health insurance are quietly preparing to stop paying for these same drugs by 2027. The collision between these two forces is beginning to worry the doctors who have traditionally managed weight and metabolic disease: primary care physicians who see patients regularly, know their full medical histories, and have nowhere to hide if something goes wrong.
The concern from primary care doctors centers on oversight and continuity. When a telehealth platform prescribes a GLP-1 drug, the interaction is often transactional—a video visit, a prescription, a shipment to the patient's door. There is no ongoing relationship, no chance to monitor for side effects over months, no integration with the patient's other medications or conditions. A primary care doctor who has been seeing a patient for years knows whether that person has a history of thyroid cancer, or pancreatitis, or a family predisposition to certain complications. A telehealth prescriber working from a checklist does not have that context. The worry is not that telehealth companies are acting in bad faith, but that the structure of their business—fast, efficient, remote—is fundamentally misaligned with the kind of medicine obesity treatment requires.
Meanwhile, the economic pressure is building from above. Major US employers, facing the spiraling cost of these medications as more workers request them, have begun signaling that they will drop GLP-1 coverage from their health plans starting in 2027. The drugs are expensive—a year's supply can cost thousands of dollars—and as obesity rates remain high and awareness of these medications spreads, the number of employees seeking them has grown. For employers, the math is simple: cut the benefit, reduce the liability. For workers, the consequence is starker. Those who have been taking these drugs and seeing results will face a choice: pay out of pocket at full price, stop the medication, or find another way.
This creates a peculiar and troubling gap in the market. Telehealth companies, which operate on thin margins and rely on volume, will have strong incentive to serve the patients who can pay privately or who have insurance that still covers the drugs. Primary care doctors, who have long been the gatekeepers of obesity treatment but who are often underpaid for the time it takes to manage these cases properly, may find themselves sidelined. And patients—particularly those in the middle, earning too much for government assistance but not enough to absorb the full cost of these medications—may find themselves with nowhere to turn.
The tension reflects a deeper fracture in how America delivers and pays for medical care. Telehealth has genuine advantages: it expands access, reduces barriers to seeing a doctor, and can serve rural areas where primary care is scarce. But it also fragments care, turning complex medical decisions into discrete transactions. Employers, meanwhile, are responding rationally to costs that have become unsustainable, but their response will inevitably push some patients toward less oversight, not more. The primary care doctors sounding the alarm are not opposed to telehealth or to these medications. They are worried about what happens when the incentives stop aligning with good medicine—when speed and cost-cutting become the organizing principles, and the patient's long-term health becomes secondary to the transaction.
What emerges over the next year will likely be a two-tiered system: one for patients with resources or comprehensive insurance, served by a mix of primary care and telehealth providers; another for everyone else, served primarily by telehealth companies operating in a largely unregulated space, with minimal oversight and no continuity of care. The question is whether that fragmentation will ultimately harm the patients these drugs are meant to help.
Notable Quotes
Primary care doctors worry that telehealth's transactional model lacks the ongoing relationship and medical context needed for safe obesity treatment.— Primary care physicians
Employers are responding to unsustainable medication costs by eliminating GLP-1 coverage from health plans.— US employers
The Hearth Conversation Another angle on the story
Why are primary care doctors specifically worried about telehealth companies prescribing these obesity drugs? Aren't they just expanding access?
They are expanding access, yes. But access without continuity is a different thing. A primary care doctor sees the same patient over years. They know the full picture. A telehealth visit is a snapshot.
What's the actual risk? These drugs have been used for years.
The drugs themselves are safe when prescribed correctly. The risk is in the prescribing—knowing which patients shouldn't take them, catching side effects early, adjusting doses based on how the patient is actually doing. That requires relationship and time.
And the employers dropping coverage—that's purely about cost?
Purely. These drugs are expensive, and as more people find out about them, more people want them. The cost curve becomes unsustainable for an employer. So they cut it.
But that leaves patients in the middle—not poor enough for government help, not rich enough to pay full price.
Exactly. And those patients will still want the medication. So they'll turn to telehealth companies, which will be happy to serve them. But now there's even less oversight.
So the system is fragmenting.
It's not fragmenting—it's already fragmented. This is just making it worse. The people with good insurance and a good primary care doctor will do fine. Everyone else gets a transaction.